Compare MSD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | PLX |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 168.1M |
| IPO Year | N/A | 1998 |
| Metric | MSD | PLX |
|---|---|---|
| Price | $7.64 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 70.2K | ★ 825.9K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $30.69 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $6.11 | $1.32 |
| 52 Week High | $7.46 | $3.10 |
| Indicator | MSD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 68.87 | 60.56 |
| Support Level | $7.49 | $2.03 |
| Resistance Level | $7.52 | $2.11 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 92.86 | 85.92 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.